Literature DB >> 10594687

Suppression of the reactive oxygen intermediates production of human macrophages by colorectal adenocarcinoma cell lines.

A Siegert1, C Denkert, A Leclere, S Hauptmann.   

Abstract

Although some in vitro studies indicate that macrophages exert cytotoxic responses against tumour cells by production of reactive oxygen intermediates (ROI), no obvious impairment of tumour cell growth is visible in various human malignant tumours, which contain a large number of tumour-associated macrophages (TAM). We made use of an in vivo-like co-culture model of multicellular tumour spheroids of three colon carcinoma cell lines (HRT-18, HT-29, CX-2) and three functionally different phenotypes of human macrophages (27E10, RM3/1, 25F9) to investigate if tumour cells deactivate macrophage cytotoxicity. The production of ROI was measured by a lucigenin-amplified chemiluminescence assay in a 96-well-microplate luminometer. Different capabilities to produce ROI by different macrophage phenotypes were observed. However, independent of the macrophage phenotype and the tumour cell type a significant inhibition of ROI formation was found in co-cultures after 1 hr, 1 and 2 days. Macrophages were also suppressed by tumour cell supernatants, which contained anti-inflammatory cytokines transforming growth factor-beta1 (TGF-beta1) and negligible levels of interleukin-4 (IL-4) and IL-10 as shown by enzyme-linked immunosorbent assay (ELISA). Although recombinant human cytokines TGF-beta1, IL-10 and IL-4 inhibited the production of ROI in freshly isolated monocytes, these cytokines had no effect on differentiated macrophage phenotypes, indicating that these cytokines are not involved in mediating tumour-induced suppression of ROI production by human macrophages.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10594687      PMCID: PMC2326977          DOI: 10.1046/j.1365-2567.1999.00915.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  25 in total

1.  Macrophage-mediated induction of DNA strand breaks in target tumor cells.

Authors:  Y C Chong; G H Heppner; L A Paul; A M Fulton
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

2.  A monoclonal antibody to a novel differentiation antigen on human macrophages associated with the down-regulatory phase of the inflammatory process.

Authors:  G Zwadlo; R Voegeli; K Schulze Osthoff; C Sorg
Journal:  Exp Cell Biol       Date:  1987

3.  A monoclonal antibody to a differentiation antigen present on mature human macrophages and absent from monocytes.

Authors:  G Zwadlo; E B Bröcker; D B von Bassewitz; U Feige; C Sorg
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

Review 4.  Macrophage heterogeneity.

Authors:  G J Dougherty; W H McBride
Journal:  J Clin Lab Immunol       Date:  1984-05

5.  Deactivation of macrophages by transforming growth factor-beta.

Authors:  S Tsunawaki; M Sporn; A Ding; C Nathan
Journal:  Nature       Date:  1988-07-21       Impact factor: 49.962

6.  IL-4 inhibits superoxide production by human mononuclear phagocytes.

Authors:  S L Abramson; J I Gallin
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

7.  Epstein-Barr virus BCRF1 gene product (viral interleukin 10) inhibits superoxide anion production by human monocytes.

Authors:  H Niiro; T Otsuka; M Abe; H Satoh; T Ogo; T Nakano; Y Furukawa; Y Niho
Journal:  Lymphokine Cytokine Res       Date:  1992-10

8.  Sensitivity of tumoricidal function in macrophages from different anatomical sites of cancer patients to modulation of arachidonic acid metabolism.

Authors:  D P Braun; M C Ahn; J E Harris; E Chu; L Casey; G Wilbanks; K P Siziopikou
Journal:  Cancer Res       Date:  1993-07-15       Impact factor: 12.701

9.  Changes in mechanisms of monocyte/macrophage-mediated cytotoxicity during culture. Reactive oxygen intermediates are involved in monocyte-mediated cytotoxicity, whereas reactive nitrogen intermediates are employed by macrophages in tumor cell killing.

Authors:  J H Martin; S W Edwards
Journal:  J Immunol       Date:  1993-04-15       Impact factor: 5.422

10.  Purification of macrophage deactivating factor.

Authors:  S Srimal; C Nathan
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

View more
  4 in total

Review 1.  TGFβ biology in cancer progression and immunotherapy.

Authors:  Rik Derynck; Shannon J Turley; Rosemary J Akhurst
Journal:  Nat Rev Clin Oncol       Date:  2020-07-24       Impact factor: 66.675

2.  Enhancement of nitric oxide release in mouse inflammatory macrophages co-cultivated with tumor cells of a different origin.

Authors:  Lido Calorini; Francesca Bianchini; Antonella Mannini; Gabriele Mugnai; Salvatore Ruggieri
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Dual role of macrophages in the response of C26 colon carcinoma cells to 5-fluorouracil administration.

Authors:  Laura Patras; Alina Sesarman; Emilia Licarete; Lavinia Luca; Marius Costel Alupei; Elena Rakosy-Tican; Manuela Banciu
Journal:  Oncol Lett       Date:  2016-06-13       Impact factor: 2.967

4.  Tumor-associated macrophages in clear cell renal cell carcinoma express both gastrin-releasing peptide and its receptor: a possible modulatory role of immune effectors cells.

Authors:  Jens Bedke; Bernhard Hemmerlein; Christina Perske; Andreas Gross; Markus Heuser
Journal:  World J Urol       Date:  2009-12-13       Impact factor: 4.226

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.